Adenosine receptors as promising targets for the management of ocular diseases

Eleonora Spinozzi1 · Cecilia Baldassarri1 · Laura Acquaticci1 · Fabio Del Bello1 · Mario Grifantini1 · Loredana Cappellacci1 · Petrelli Riccardo1

Received: 2 November 2020 / Accepted: 1 December 2020 / Published online: 25 January 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021

Abstract
The ocular drug discovery arena has undergone a significant improvement in the last few years culminating in the FDA approvals of 8 new drugs. However, despite a large number of drugs, generics, and combination products available, it remains an urgent need to find breakthrough strategies and therapies for tackling ocular diseases. Targeting the adenosinergic system may represent an innovative strategy for discovering new ocular therapeutics. This review focused on the recent advance in the field and described the numerous nucleoside and non-nucleoside modulators of the four adenosine receptors (ARs) used as potential tools or clinical drug candidates.

Keywords Adenosine receptors (A1AR · A2AAR · A2BAR · A3AR) · Ocular diseases · Glaucoma · Intraocular pressure · Dry eye · Retinal inflammation

Abbreviations
AC        adenyl cyclase
AH        aqueous humor
ADME      Absorption, Distribution, Metabolism, and Excretion
AMD       age-related macular degeneration
ARs       adenosine receptors
CHF       congestive heart failure
DE        dry eye
DR        diabetic retinopathy
ERK       signal-regulated kinase
HCC       hepatocellular carcinoma
INL       the inner outer layer
IOP       intraocular pressure
IP3       inositol triphosphate
MMP-2     matrix metalloproteins
NASH      nonalcoholic steatohepatitis
NFL       nerve fiber layer
NPE       non-pigmented ciliary epithelial
NTPDase   ecto-nucleoside triphosphate diphosphohydrolase
ONH       optic nerve head
ONL       outer nuclear layer
PACG      primary angle-closure glaucoma
PD        Parkinson’s disease
PLC       phospholipase C
POAG      primary open-angle glaucoma
RGCs      retinal ganglion cells
RNFL      retinal nerve fiber layer
ROCK      rho kinase
RPE       retinal pigment epithelium
SC        scleroderma
SNMS      servo-null micropipette system
TM        trabecular meshwork
VEGF      vascular endothelial growth factor

Introduction
The eye is a unique and complex organ considered the “window to the brain” and the disruption of any of its tissues can end up in ocular discomfort, visual impairment, or loss of vision. Its anatomical complexity makes extremely
difficult the understanding of disease pathogenesis and ophthalmic drug discovery challenging. With respect to other tissues of the human body, the eye owns several unique features. It is an immune-privileged site that actively restrains some immune and inflammatory responses due to the presence of the blood-retinal barrier (BRB). BRB is a physical barrier that allows solutes’ movements across the vascular bed and affords a primordial defense from invaders. Moreover, some of his tissues are transparent and avascular, making the eye easy to reach clinically.

Recent data released by WHO reported that about 1 billion people suffer from vision impairment, and most of them are over 50 years [1]. It seems evident that the leading causes of visual impairment are age-related and include the following ocular diseases: glaucoma, dry eye (DE), retinal inflammation, age-related macular degeneration (AMD), and diabetic retinopathy (DR).

Glaucoma is an aetiologically complex optic neuropathy distinguished by the accelerated death of axons and retinal ganglion cells (RGCs). Regrettfully, it is considered the second most frequent cause of irreversible blindness worldwide [2–4]. In 2014, Tham et al. have performed a systematic population-based meta-analysis study anticipating that the global glaucoma burden will grow from 76 million in 2020 to 112 million in 2040, mainly affecting people living in low-income countries such as Africa and Asia [5]. The disease covers a broad and complex group of optic neuropathies by a progressive loss of RGCs and associated alterations in the optic nerve head (ONH) and the retinal nerve fiber layer (RNFL), with resultant vision loss [6]. Even though the exact explanation of the etiopathogenesis is yet unclear, the elevation of intraocular pressure (IOP) represents the only known treatable risk factor [7]. Hence, IOP might be considered the pillar target in contemporary glaucoma management [8], and its reduction is deemed as the primary efficacy endpoint in almost all ongoing glaucoma clinical trials.

Primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG) are the two most common primary glaucoma types. Although they have some common characteristics, they have completely different etiopathogenesis, leading up to different pharmacological approaches. POAG is the most prevalent type of glaucoma in western Europe and the United States. On the contrary, PACG is highly frequent in China and other Asian countries.

A broad range of pharmacological and surgical options are available for glaucoma treatment, including eye drops and laser procedures. All are meant to protect the optic nerve by decreasing eye pressure. In spite of the full availability of different options, eye drops often represent the first choice for treating patients. Eye pressure can be safely controlled for many years using a combination of drugs and laser treatments. The mechanism of action by which the eye drops operate through is by helping the eye’s fluid to drain off or by cutting down the fluid load produced by the eye. Drug treatments used for glaucoma management are ranked based on their active components, including carbonic anhydrase inhibitors, alpha agonists, beta-blockers, and prostaglandin analogs. Patients who demand more than one type of medication are often treated with a combination of different drugs. The older class of cholinergic agonists (such as carbachol and pilocarpine) represents the first class of drugs used to manage glaucoma and operates by lowering IOP through increasing aqueous humor (AH) outflow. However, due to their severe systemic side effects, they have now fallen into disuse. The brand-new FDA-approved rho kinase (ROCK) inhibitor, Rhopressa® (Netarsudil ophthalmic solution, Aerie Pharmaceuticals), reduces IOP by lowering the elevated pressure in patients with POAG or ocular hypertension. The drug exerts its pharmacological effect by increasing the outflow of AH or by the inhibition of norepinephrine transport along with reducing the episcleral venous pressure [9]. Just recently, the US FDA approved Roclatan® (a combination of latanoprost and netarsudil) to manage POAG [10]. The combination relies on the ability of netarsudil to lowering IOP complemented by the latanoprost-mediated increase of outflow. Vyzulta® (latanoprostene ophthalmic solution, LBN), licensed by Bausch & Lomb and FDA approved in 2017, is nitric oxide (NO)-donating PGF2α analog that demonstrated a high potential for lowering IOP [10].

The DE syndrome is often known by a variety of terms ranging from keratitis sicca, keratoconjunctivitis sicca (KCS), to dysfunctional tear syndrome. In DE the eye turns into dry either because there are not enough tears being produced or because there is an abnormal evaporation of tears. In an eye suffering from DE, the tears’ content seems to be impaired with a lesser concentration of proteins, and one of the characteristic features of DE is ocular surface inflammation. Tear supplements represent the first-line treatments for mild dry eye disease (DED), whereas cyclosporine and Lifitegrast® result to be appropriate choices in patients with more severe symptoms [11].

Neuroinflammation, a feature of chronic neurodegenerative diseases, plays an essential role in several retinal degenerative diseases’ pathophysiology [12]. The retina is a complex and highly organized tissue made of neuronal and non-neuronal cells. Neurons aside, the retina also contains endothelial cells, pericytes, and glial cells named astrocytes, microglia, and Müller cells. An intact BRB is essential in protecting neural tissues from harmful materials and maintaining the retina’s neural functions. It is well documented that an inflammatory insult impacts negatively on the BRB’s integrity. The immune cells respond to an insult by secretion of pro-inflammatory cytokines that contribute to
endothelial cell dysfunction, inducing retinal cell death, and BRB breakdown. It has been reported that a pro-inflammatory environment is a breeding ground for the onset of glaucoma and DR. Based on these findings, fighting the actions of pro-inflammatory cytokines has been proposed as an innovative therapeutic strategy for managing retinal inflammation [13].

AMD is the leading cause of severe and irreversible loss of vision in patients aged 60 or over [14]. This disease causes damage to the macula, the central part of the retina responsible for high-resolution vision, and is due to an anomaly (e.g., structural changes and a general decline of essential functions) of retinal pigment epithelium (RPE) [15]. Current known risk factors include age, people with a family history of AMD, smokers, ethnicity (high incidence in Caucasians), gender (high incidence in women), and race. Anti-vascular endothelial growth factor (VEGF) therapy is regarded as the first-line treatment for AMD and aims to reduce edema and neovascularization (new blood vessel growth). Anti-VEGF therapy has tremendously decreased the prevalence of AMD globally [16].

DR is a complication of diabetes mellitus that leads to vision loss through progressive damage in retinal blood vessels [17]. People of all ages who have had diabetes for more than 20 years have the maximum probability of developing DR. The recent therapeutic trend for managing DR foresees the intravitreal administration of anti-VEGF with the goal of improving vision with fewer side effects. On the other side, the laser therapy facilitates to stabilize the vision.

The ocular therapeutic field has achieved significant improvements in the last decade, as evidenced by the FDA approval of Lifitegrast® (an integrin antagonist) for DE, Brolucizumab* (a recombinant humanized antibody fragment) for wet AMD, Rocalatan® (a combination product), Vyzulta® (a NO-donating PGF2α analog), and Rhopressa® (ROCK inhibitor) for glaucoma, Luxturna® (gene therapy) for retinitis pigmentosa and Dextenza® (a corticosteroid) for ocular inflammation. However, despite all the efforts to develop new drugs, generics, and innovative therapies, the successful management of ocular diseases still lingers as an unmet medical need.

Among the multitude of transmitters/modulators present in the eye, nucleosides and nucleotides emerge as peculiar molecules able to regulate many physiopathological and biochemical processes.

For this reason, the purinergic signaling pathways are increasingly becoming recognized in ophthalmology as a potential target for pharmaceuticals. In particular, the adenosine signaling pathway, including its sub-receptor biology, is increasingly being investigated to develop new ophthalmic drugs. Different categories of agonists and antagonists of various subtypes of G protein-coupled receptors such as adenosine receptors (ARs) and P2Y receptors (P2YRs), and ATP-gated P2X receptor ion channels (P2XRs) are currently under investigation as potential agents for the treatment of DE, ocular inflammation, and glaucoma [18–20]. Three out of four subtypes of ARs (A1, A2A, and A3, respectively) have extensively been exploited to treat eye disorders, yielding some clinical candidates [21–23].

It is also worth mentioning that extracellular concentrations of dinucleotide polyphosphates are significantly increased in pathological states, activating P2YRs and P2XRs throughout the eye. P2YRs and P2XRs have multiple functions in the eye, and their modulation has been explored for ophthalmic drug discovery purposes. P2Y2R and P2Y6R agonists lower IOP, whereas the P2X7R antagonists thwart the ATP-induced neuronal apoptosis in the retina. For the above reasons, the modulators of the “purinome” present in the eye might represent a valuable source of new therapeutic options for ocular diseases. In this context, this review provides an overview of recent ocular drug discovery literature covering this emerging and dynamic field.

**Rationale for treating ocular diseases via adenosine receptor agonists and antagonists**

The endogenous nucleoside modulator adenosine is continuously produced both at the intracellular and extracellular levels. It has a very short half-life (~1.5 s), and it is quickly metabolized to inosine and hypoxanthine. In the CNS, adenosine controls synaptic activity, neurotransmitter release, and neuronal excitability, acting as a neuromodulator. It may also act as an intracellular messenger embroiled in pathological and physiological processes (e.g., inflammation). Low extracellular levels of adenosine (in the nanomolar level) are deemed as positive signs of cellular homeostasis, as usually occurs during physiological conditions. In response to cellular stress or pathological conditions (e.g., ischemia or tissue hypoxia), the adenosine levels considerably increase, reaching the micromolar range [24]. If we compared the normotensive individuals with ocular hypertensive patients, it could easily be observed that the adenosine levels in AH are significantly boosted [25, 26].

The biological functions of adenosine are mediated by activation of four different G-coupled ARs: A1AR, A2AAR, A2BAR, and A3AR, respectively. All of them are implicated in inhibiting and stimulating cyclic AMP (cAMP) production in several manners. By giving details, A1AR and A3AR down-regulate cAMP levels inhibiting adenyl cyclase (AC), whereas A2AAR and A2BAR activate AC, boosting cAMP production.
Besides being widely distributed in the whole body, ARs are worthy of special mention in numerous ocular tissues such as the ciliary body, trabecular meshwork (TM), scleroderma (SC), and retina [27]. Activation or inactivation of ARs crashes onto AH formation, outflow, and as a consequence on IOP homeostasis. Furthermore, ARs are implicated in retinal function neuronal, deeply affecting neuronal survival and blood flow [25]. For the above reasons, the modulation of ARs has been explored for several decades as an insightful strategy for treating ocular diseases. Nowadays, there is a readily-available arsenal of potent agonists and antagonists associated with each of the four AR subtypes. However, cautiousness shall be used when they are applied to pharmacological experiments due to the selectivities that are not completely unequivocal for each AR subtype [19, 20]. For example, the A1AR agonist R-phenyl isopropyl adenosine (R-PIA, 1, Fig. 1) causes reductions in body temperature and heart rate in mice which are dependent on the presence of the A3 subtype. Indeed, genetic knockout of the A3AR corroborates this hypothesis and prevents some of these effects [19, 26].

A1AR agonists

The A1AR was the first AR to be cloned and is widely expressed in the brain and peripheral tissues (e.g., kidney, liver, heart, smooth muscle, fat cells, and eye) [28]. Just recently A1AR has been well characterized in the retina of Rhesus monkey and has been localized on the outer plexiform layer (OPL), in the RPE, in the ganglion cell layer (GCL), and on photoreceptors [29]. A1AR plays an essential role in inflammation, and in the brain the activation of A1AR weakens the ischemic neuronal impairment [30]. Retinal ischemia phenomenon is attributable to glaucoma, diabetes, central artery occlusion, and retinopathy and always ends up with vision loss. The activation of A1AR by selective agonists protects against ischemic impairment, probably through a mechanism that involves Müller cells. Unfortunately, this protection depends on ischemia duration and is not effective in prolonged ischemia. Another effect of A1AR activation is the attenuation of the damage caused by N-methyl-D-aspartate (NMDA). Adenosine acts as a neuromodulator of RGCs by inhibiting the glutamate-induced calcium influx through the A1AR activation. In addition, adenosine binds to A1AR present on the TM, increasing the AH outflow through secretion of matrix metalloproteins (MMP-2) [31]. This process has the effect of lowering IOP [32].

Adenosine is the primary endogenous agonist of the A1AR, whereas countless A1AR agonists with every disparate modification at ribose moiety and the adenine N6 and C2 positions have been disclosed in the last two decades [33–40]. Before the discovery of the A3 subtype, several agonists have been identified as selective for A1AR (Fig. 1) since it has been defined their A1AR selectivity based on their affinity at the rat A1AR vs. A2AAR [41]. However, a comparison of N6-cyclopentyladenosine (CPA, 2) and N6-cyclohexyladenosine (CHA, 3) binding affinities at the four human ARs showed only a limited A1AR selectivity compared to the A3AR [20]. Later on, the A1AR full agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 4, Fig. 1) showed lower than full efficacy at the A3AR, acting as a partial agonist or an antagonist [42] and (S)-ENBA (5, Fig. 1) emerged as an extremely selective A1AR agonist (> 1000-fold) respect to rat and human A3AR [43].
However, among the most selective A1AR agonists deserve particular mention 5′-chboro-5′−deoxy-N6−(±)−endo-norborn-2-yl-adenosine (5′Cl5′(±)-ENBA or 5′-Cl-ENBA, 6), developed in our laboratory, which had exceptionally high A1AR affinity and selectivity versus the other AR subtypes [44, 45].

Trabodenoson (INO-8875, PJ-875, Fig. 2), the 5′-nitrate ester derived from CPA, was developed using a 3D structure and rational drug design techniques to create adenosine mimetic with a high affinity and selectivity for the A1AR (K_i = 0.97 nM, partial agonist). Based on trabodenoson’s high selectivity, a consistent reduction in IOP has been observed without the transient IOP increase associated with other less specific compounds that interact with other AR subtypes [21, 46]. Based on this finding, it reached the clinical trials in 2015 as an ophthalmic formulation for ocular hypertension (OHT) and POAG [47] and advanced in the phase 3 trial (ClinicalTrials.gov Identifier: NCT02565173). Unfortunately, the development was discontinued in 2017 due to failure to achieve its primary endpoint to better reduce IOP compared to placebo [23]. Despite not yet published, an important study of phase 2 (NCT02829996) reported the combination of trabodenoson (two different doses 3.0% and 6.0%) and latanoprost (NCT02829996) reported the combination of trabodenoson and latanoprost (NCT02565173). Unfortunately, the development was discontinued in 2017 due to failure to achieve its primary endpoint to better reduce IOP compared to placebo [23]. Despite not yet published, an important study of phase 2 (NCT02829996) reported the combination of trabodenoson (two different doses 3.0% and 6.0%) and latanoprost (NCT02565173).

As recently reported by us, 5′-Cl-ENBA can reduce pain in the formalin test or prevent mechanical allodynia and thermal hyperalgesia in the spared nerve injury (SNI) model of neuropathic pain in mice, without exerting any drawbacks on motor coordination and blood pressure [49, 50]. It has also been reported that it can decrease L-DOPA-induced dyskinesia and locomotor activity in a mice model of Parkinson’s disease (PD) [51], as well as the harmaline-induced tremor in rats [48].

The advantage of 5′-Cl-ENBA over the other A1AR agonists lies in the fact that at effective doses, it does not affect either motor coordination, blood pressure, or heart rate, corroborating the hypothesis that it is scarcely active on the peripheral A1AR. Ossowska et al. has recently investigated 5′-Cl-ENBA as a potential antipsychotic agent [52]. The authors reported that the hyperlocomotion induced by either amphetamine (1 mg/kg sc) or MK-801 (dizocilpine) (0.3 mg/kg ip) was inhibited by 5′-Cl-ENBA (0.1 mg/kg ip). A selective A1AR antagonist entirely reverted the effect.

5′-Cl-ENBA has never been studied in experimental models of glaucoma and ocular hypertension. However, given its high selectivity at A1AR and the distinctive feature to not generate cardiovascular drawbacks, it should be taken into consideration for further studies.

Non-nucleoside A1AR partial agonists

As a consequence of the crucial involvement of A1 agonists in heart rate and blood pressure regulation, the therapy for glaucoma or ocular hypertension built on A1AR agonists suffers from significant limitations [53]. For this reason, several non-nucleoside A1AR partial agonists have been developed [54]. The rationale for using A1AR partial agonists is based on avoiding receptor desensitization and on achieving a specific tissue selectivity of the effects without generating drawbacks [55, 56].

In 2012 Bayer HealthCare Pharmaceuticals patented a series of dicyanopyridine derivatives as potential therapeutic agents for the treatment and/or prophylaxis of glaucoma and ocular hypertension. As the outcome, the authors found out that some dicyanopyridine derivatives, and specifically capadenoson (BAY68-4986, 9, Fig. 3), lower IOP after topical eye application without affecting hemodynamics and the cardiovascular system [57]. Capadenoson (9) has been in the clinical evaluation (phase 2) in patients with persistent or permanent atrial fibrillation (AF) and angina pectoris (NCT00568945 and NCT00518921). However, 9 was withdrawn when it failed to show heart rate reduction for patients with atrial fibrillation. Just recently, it has been reported that 9 also activated human A2AAR, even though the affinities at A1AR and A2AAR were not entirely comparable [58].
Neladenoson bialanate (BAY1067197, Fig. 3), a dipeptide ester prodrug of neladenoson, has been clinically evaluated by Bayer HealthCare Pharmaceuticals in patients with chronic heart failure (NCT03098979). Unfortunately, the expected beneficial cardiac effects have not been proven while it has been observed a consistent impairment in renal function [59]. For these reasons, in 2020, Bayer decided to do not further support the development of 10, and the drug has been discontinued (NCT04320771).

A1AR antagonists

While the activation of A1AR lowers IOP in rabbits and monkeys ([60]; Tian et al., 1997), the selective action of A1AR antagonists such as DPCPX (11), 8-(p-sulfophenyl) theophylline (8-SPT, 12), and deronofylline (SLV320, 13, Fig. 4) raises IOP instead [61]. In a pioneering work aimed to evaluate the role of AR activation in epinephrine-induced changes in ocular function, Crosson et al. reported that 8-SPT (12) enhanced initial hypertension by inhibiting the epinephrine-induced reduction in IOP [62]. On the other hand, the A1AR antagonists DPCPX diminished recovery after retinal ischemia in rats, while an A2AAR antagonist considerably protected the retinal function and structure even with long-lasting ischemia [63].

The pyrrolo-pyrimidine derivative 13 has never been studied as potential drug candidate for ocular diseases. However, it is in phase 2 clinical trials by Abbvie (previously Solvay Pharmaceuticals and Abbott) for the treatment of congestive heart failure (CHF) and renal failure (NCT00568009). Although it has completed a phase 2 trial, no recent developments have been reported.

Taken together, those data support the idea that A1AR antagonists hold few promises as ocular drug candidates, given the fact they increase IOP in mice and rabbits [25].

A2AAR agonists

The human A2AAR was identified in 1992 and has been localized in the retina in several places, including GCL, outer nuclear layer (ONL), and the inner outer layer (INL) [64]. A2AAR has also been detected in microglia and Müller cells [65]. In the last decade, A2AAR has been extensively explored as a potential therapeutic target for lowering IOP or treating retinal disorders. Recently, it has been emphasized that its role played in neuroinflammation, and the modulation of its activity can shield the retinal cells from an inflammatory insult [13, 66].

A2AAR agonists and antagonists have also been widely investigated as ocular disease therapeutics, with particular reference to glaucoma [67]. Selective A2AAR agonists are typically amended at the C2 position and modified at the C5′ of the ribose ring.

A shortlist of A2AAR agonists that have demonstrated to lower IOP and to be useful for the treatment of glaucoma included: OPA-6566 (structure not disclosed), CGS-21680 (14), 2-O-Ado (15), 2-CN-Ado (16), and ATL-313 (17) (Fig. 5).

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Acucela, Inc. in September 2010 signed a co-development and co-commercialization agreement for the development of OPA-6566 for the management of POAG or ocular hypertension. OPA-6566 went through phase 1 and 2 clinical trials (NCT01410188) due to its ability to lowering IOP by enhancing AH outflow via the TM. The trial has been recently completed, but no results have yet been released. Although this Otsuka Pharmaceutical decided to end up its participation in further development activities (e.g., glaucoma) for OPA-6566, exercising its contractual right to terminate the agreement with Acucela. Acucela is now called Kubota Vision and in 2019, announced to have...
discontinued the phase 1 and 2 for managing glaucoma and ocular hypertension in the US.

In 2005 Konno et al. conducted a study with CGS21680 \((14)\) and the 2-alkynyladenosine derivatives 2-O-Ado \((15)\), and 2-CN-Ado \((16)\) in order to clarify the mechanism underlying the changing of IOP observed in rabbits \([67]\). The results showed that \(15\) and \(16\) decreased the IOP significantly in a concentration-dependent manner, whereas the relatively selective \(A_{2A}\)AR agonist \(14\) slightly decreased IOP. Also, \(15\) and \(16\) remarkably increased cAMP levels in the AH after 60 min of their administration. The authors stated that the observed IOP decreasing could be linked to increasing of cAMP levels induced by \(15\) and \(16\), mediated by a rise in outflow facility.

Evodenoson (ATL-313, DE-112, \(17\), Fig. 5), a more stable urethane-containing analog of apadenoson \((18)\), Fig. 5), has been developed by Santen Pharmaceutical, capitalizing on its property of lowering IOP \([23]\). In 2012 Santen completed a phase 1/2 clinical trial investigating the safety and efficacy of ATL-313 in lowering IOP in patients with POAG or ocular hypertension (NCT01279083). The study results have been submitted to ClinicalTrials.gov but are not yet publicly available.

Over the past two decades, Pfizer developed an extensive series of \(N^6-(2,2\text{-diphenylethyl})\)-adenosine analogs acting as potent and selective \(A_{2A}\)AR agonists, and UK-432097 \((19)\), Fig. 6) has emerged as the best-in-class \([68]\). It has been clinically developed in phase 1 for asthma and phase 2 for chronic obstructive pulmonary disease (COPD, NCT00430300), failing on both. It was discontinued in 2008 for lacking efficacy \([69]\).

Despite all efforts, the potentiality of \(A_{2A}\)AR agonists for the treatment of ocular diseases is uncertain since they have revealed both unfavorable and favorable effects in preclinical and clinical studies \([19, 20]\).

It is worth mentioning that \(A_{2A}\)AR agonists had an anti-inflammatory role in RGCs subjected to elevated pressure \([70]\). As reported by Ahmad et al., the administration of CGS-21680 \((14)\) significantly attenuated the expression of inflammatory mediators (e.g., ICAM-1, IL-6, and TNFα) and cell death markers in a mouse model of traumatic optic neuropathy (TON) \([66]\). TON is one of the significant visual repercussions of severe head trauma. The anti-inflammatory effect of \(14\) is mediated by blocking extracellular signal-regulated kinase (ERK) activation and further cytokine release in TON. The role played by \(A_{2A}\)AR in TON has also
been evaluated in A2AAR knockout mice, uncovering its potential as a therapeutic target in TON. Given that inflammation is a key player in the pathogenesis of glaucoma [71–73], A2AAR agonists might be helpful. Another crucial function that they have shown, together with A1AR agonists, is to reduce vascular resistance and increase blood flow to the retina and ONH [25].

**A2AAR antagonists**

Over the years, several A2AAR antagonists have been synthesized, and if we would divide them by relying on their chemical structure, they can be split into xanthine and nonxanthine derivatives [74]. The xanthine derivative istradefylline (KW6002, 20, Fig. 7), developed by investigators at Kyowa Hakko Kirin, has been one of the first potent A2AAR antagonists reported. Recently Boia et al. [75], reported that the blockade of A2AAR might represent a therapeutic option for the treatment of retinal ischemic diseases (e.g., transient retinal ischemia). For this reason, they evaluated KW6002 against the damage induced by ischemia-reperfusion (I–R). Its oral administration after inducing ischemia reduces microglia reactivity and inflammatory response considerably, affording retina protection. This seminal work has laid the basis for further studies on.

A2AAR antagonists as potential tools for managing retinal ischemic or neurodegenerative diseases. After being approved in Japan in 2013 to treat PD, istradefylline was launched in 2019 in the US (product name: NOURIANZ™) as an add-on therapy to levodopa/carbidopa in adults who are experiencing off episodes. The approval was based on its success in 4 clinical studies that included around 1200 participants. In January 2020, Kyowa Kirin Co., Ltd. announced that its marketing authorization application (MAA), as an adjunctive treatment for PD, had been validated by the European Medicines Agency (EMA).

Highly potent A2AAR antagonists of the new generation are represented by triazolotriazine ZM-241385 (21, Fig. 8), the triazolopurinimidine vipadenant (BII014, V2006, 22), and the pyrazolotriazolopyrimidine SCH-412348 (SCH-58261, 23). The highly potent and selective A2AAR antagonist, ZM-241385 (21), also binds to the human A2BAR with moderate affinity, and its structure in complex with thermostabilised A2AAR adenosine has been reported [76]. 21 also behaves as an inverse agonist [77]. Recently Liu et al. reported the effect of ZM-241385 on microglial activation in experimental glaucoma [78]. The authors showed that ZM-241385 might downregulate the activation of pro-inflammatory cytokines and microglia under the conditions of a high concentration of glutamate and chronic ocular hypertension. They assume this could be one of the plausible mechanisms that protected RGCs in experimental glaucoma. Surprisingly, 21 failed to protect the RGCs, presumably because they own long axons that have to deal with more challenges.

Vipadenant (BII014, V2006, 22), initially discovered by Juno Therapeutics and then acquired by Vernalis and Ligand Pharmaceuticals, is a selective A2AAR antagonist developed as an oral drug for the treatment of PD (phase 2) but later discontinued due to safety concerns [74, 79]. Vipadenant was then licensed out to RedoxTherapies because of its high potential to disrupt an immunosuppressive mechanism of tumor protection [80]. When used in combination with other anticancer drugs, vipadenant is able to generate an improved efficacy for immunotherapies targeting different cancers. Vipadenant is currently in preclinical trials for cancer in the US.
The potent and selective A2AAR antagonist SCH-412348 (SCH-58261, 23) has been initially identified and developed by Schering-Plough as a potential treatment for neurological conditions such as depression and PD. Given that 23 suffered from poor solubility and was not active when orally dosed, it has been discontinued after having completed phase 2. Starting from the observation that the blockade of A2AAR prevents the neuroinflammatory response and can improve recovery of retinal function after exposure to elevated hydrostatic pressure (EHP), Madeira et al. investigated SCH-412348 [73, 81]. Their results showed that 23 attenuated the release of pro-inflammatory cytokines and the microglia reactivity. Moreover, it prevented ischemia-reperfusion (I-R)-induced cell death resulting from the excessive raising of IOP, by attenuating the neuroinflammatory response. The authors concluded by suggesting that the blockade of A2AAR may play an important role in the management of retinal neurodegenerative diseases such as glaucoma and ischemic diseases.

Over the last decades, academia and the pharma industry have made significant efforts toward the discovery of potent and selective A2AAR antagonists, even if the achievement of the optimal A2AAR antagonist with adequate physico-chemical and pharmacological properties still remains a challenge.

The benzothiazole-based scaffold tozadenant (SYN-115, 24, Fig. 9), developed by Hoffmann-La Roche, represents a potent and selective A2AAR antagonist with the desired Absorption, Distribution, Metabolism, and Excretion (ADME) properties [82, 83]. 24 has been then developed for the treatment of PD by the Finnish company Biotic Therapies, which was acquired by Acorda Therapeutics in 2016. At the end of 2017, Acorda Therapeutics announced that they discontinued the development of tozadenant for the treatment of PD (phase 2, NCT02453386) and liver disorders (phase 1, NCT03212313), due to serious adverse events (e.g., agranulocytosis) and safety concerns. As of yet, no preclinical or clinical studies are ongoing or have been carried out to explore the potential use of tozadenant for the treatment of glaucoma or ocular diseases.

Inspired by the scaffold of 24 and with the goal to discover a potent and selective series of A2AAR antagonists with advantageous ADME properties, Basu et al. reported a new series of 2-substituted benzothiazole and thiazolo[5,4-c]pyridine derivatives [84]. Compound 25 emerged as a potent and selective A2AAR antagonist with desirable drug-like properties (e.g., high oral bioavailability), making it a promising drug candidate for treating PD, cancer, and ocular diseases.

To sum up, A2AAR agonists and antagonists showed multiple activities which seem to be in conflict with each other, and the current evidence that A2AAR agonists may be useful on the management of glaucoma is not yet convincing.

### A2BAR agonists and antagonists

The A2BAR has been cloned in 1992, and among the 4 adenosine subtypes remains the least studied, mostly because few selective ligands are available [85].

The evidence of A2BAR in the anterior ocular segment of bovine corneal endothelium has been for the first time reported by Blazynski, highlighting that A2BAR is present and functional in the retina [86]. Subsequently, other researchers have identified the presence of A2BAR in Müller cells and in retinal pigment epithelial cells [87, 88].

The A2BAR is implicated in inflammation in several tissues (e.g., lung, kidney, and heart) and has a critical role in hypoxic conditions and brain inflammation (e.g., Alzheimer’s disease) [89–92]. So far, very little is known about the role of the A2BAR in the eye. What is widely recognized is that A2BAR plays an important role in similar types of inflammation but occurring in different tissues, even though discrepancies between anti-inflammatory and pro-inflammatory effects have been recorded [93].

The activation of A2BAR by adenosine in retinal endothelial cells triggers the extracellular ERK pathway and boosts the levels of VEGF under hypoxic conditions [94, 95]. Considering that A2BAR is expressed in human RPE, its activation resulted in the inhibition of phagocytosis of outer photoreceptor segments [96]. On the other hand, the advantages or disadvantages of blocking A2BAR in the eye have not yet been reported.

Since the involvement of A2BAR in neuroinflammation is starting to be uncovered, it is reasonable to assume that in the next years, the role of A2BAR in the retina under pathological conditions will be better explained. Such a new scenario will open up the opportunity to explore different therapeutic options based on A2BAR ligands.

### A3AR agonists

A3AR is the last receptor to be cloned [97] and is involved in a variety of different intracellular signaling pathways, ranging from inositol trisphosphate (IP3), intracellular calcium (Ca++), and Gq protein coupling activating phospholipase C (PLC), or inhibition of AC activity through Gi coupling [98]. The pioneering studies conducted in the retina did not detect the presence of A3AR, but subsequently, the receptor has been identified in the RGCs. Then Beach et al. confirmed the presence of A3AR in RPE, RGCs, and nerve fiber layer (NFL) by investigating the distribution of ARs in the retina of Rhesus monkeys [29]. Recently has emerged the role of A3AR as a modulator of inflammation, thus making it an appealing target for treating inflammatory diseases (e.g., osteoarthritis) [99]. Regarding ocular inflammation, A3AR agonists have received much attention to treating DE syndrome and uveitis [100]. Even
the influence of A3AR activation on glaucoma, DR, and ischemic diseases has been extensively surveyed. The damage to the NFL surrounding RGCs, followed by RGC apoptotic death induced by the ATP-gated P2X7R ion channel activation, is the main feature of DR and glaucoma [101]. In chronic glaucoma, ATP is released from astrocytes of the optic nerve and triggered P2X7R resulting in apoptotic cell death of RGCs in the retina [19]. During homeostasis perturbation, cells release ATP that acts as an inflamasome activator, leading to pro-inflammatory mediators’ release. Elevated ATP levels have been found in different animal models of glaucoma, and in the retina, ATP is released by Müller cells, astrocytes, and microglia. As reported by Lu et al., in the extracellular environment, ATP can interact with P2XRs or be hydrolyzed into adenosine by the enzymatic activity of ecto-nucleoside tri-phosphate diphosphohydrolases (NTPDases) [102]. An unbalanced activity of NTPDase-1, might convert more ATP into adenosine, increasing the chance of activating ARs. Indeed, Rodriguez-Neves et al. reported that in the experimental models of glaucoma, the adenosine levels are highly enhanced [103].

A readily checked risk factor of glaucoma is considered to be the elevated IOP, which is believed to be the result of reduced AH outflow from the anterior segment. However, the role of A3AR on lowering/increasing IOP is still controversial. It is well documented that the treatment with A3AR antagonists reduced IOP in mice as well as in A3AR knockout mice experimental models, but not all reported studies on A3AR converge on the same conclusions [25, 104, 105]. For example, the case of IB-MECA (CF101, piclodenoson, 26, Fig. 10), an A3AR agonist, is emblematic because, during the clinical trials for the treatment of DE syndrome, it has been found to lower IOP [106]. This surprising result could be due to unintentional cross-activation of A1AR [107] or be linked to the chronic administration of 26 that led to lower IOP via the pharmacological mechanism known as “inversion effect” already seen for other ARs ligands and theorized by Jacobson et al. [108].

The “inversion effect” can better clarify why the pharmacological effect of an AR ligand administered in acute can be entirely reversed if it is administered chronically [109]. Since glaucoma therapy is administered chronically, the “inversion effect” should be considered when deciding to undertake a trial that involves AR ligands.

The activation of A3AR preserves RGC cells and restrains the rise in calcium levels caused by the stimulation of glutamate receptors [110]. In glaucoma and DR, the overactivation of glutamate receptors is responsible for raising of intracellular calcium concentration, which consequently ends up in cell death. Since RGCs express A3AR, the protective effect may rise up from the direct action of an A3AR agonist with those cells [88]. Galvao et al. showed that A3AR activation lowered the retinal apoptotic cell death and boosted the RGC survival rate [111]. In addition, the same authors reported that the activation of A3AR preserves the retina from retinal ischemia-reperfusion (I-R) injury, from damage induced by partial optic nerve transection, and excitotoxic-induced cell death.

26 is an orally bioavailable small molecule with a favorable therapeutic index, which is being tested in several phase 2 studies by the Israeli biopharmaceutical company Can-Fite (NCT00349466 and NCT01235234). In a phase 2 study completed in 2011 to treat plaque psoriasis, 26 successfully met all its endpoints, significantly improving the disease symptoms (NCT00428974). In a phase 2/3 study the data showed a significant clinical activity from week 16 up to 32 with the 2 mg dose daily (NCT01265667) [112], and in 2018 it entered a phase 3 study for the treatment of moderate-to-severe psoriasis (NCT03168256). Similarly, phase 2 studies demonstrated the efficacy of 26 given as a monotherapy for the treatment of rheumatoid arthritis. A phase 3 study is still active and is aimed to compare 26 to methotrexate as a first-line treatment of rheumatoid arthritis (NCT02647762).

During an early unsuccessful trial of 26 for DE syndrome (NCT01235234), researchers from OphthaliX, a subsidiary company of Can-Fite, have noted a modest reduction of IOP in patients obtaining the drug. The IOP reduction was further investigated and was found to be 0.92 mmHg at a dose of 1 mg of 26 twice daily [106]. Then OphthaliX conducted a phase 2 safety and efficacy clinical trial of orally administered 26 in patients with elevated IOP and glaucoma (NCT01033422) [113]. Unfortunately, during the 16 weeks of treatment with 26 (1 or 2 mg twice daily) of patients with
elevated IOP, no statistically significant differences were found between the placebo group and drug-treated group in the primary endpoint of lowering IOP.

Considering that 26 failed to meet its primary endpoint, OphthaliX has declared that they do not see any immediate path forward in glaucoma. The mechanistic limitation of using A3AR agonists to treat glaucoma may lie in the desensitization of ARs. For this reason, nucleoside prodrugs of A3AR agonists have been explored for their action on lowering IOP [114, 115].

26 also induced an anti-inflammatory effect in experimental autoimmune uveitis induced by retinal antigen interphotoreceptor retinoid-binding protein [116]. A phase 2 study to assess the safety and efficacy of 26 to subjects with uveitis has been planned in 2013 (NCT01905124), but later Can-Fite decided to withdraw.

Given that 26 has a full-blown anti-viral effect already protected by a US patent (US7589075), Can-Fite, in collaboration with the Lewis Katz School of Medicine at Temple University (Philadelphia), has recently started a study on the anti-viral activity of 26 on COVID-19 viral load. At the beginning of September 2020, Can-Fite received approval from the US FDA for use 26 in a phase 2 study to treat COVID-19 patients with moderate symptoms (NCT04333472).

Cl-IB-MECA (CF102, namodenoson, 27, Fig. 10), has been initially originated in the laboratory of Prof. Kenneth A. Jacobson at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and then developed by Can-Fite for the treatment of liver conditions, such as nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) [117]. The safety of 27 has been extensively demonstrated in several preclinical studies and in phase 1/2 clinical studies, proving to be safe and effective (NCT00790218 and NCT02927314). In 2012, 27 has achieved the orphan drug status from the FDA for the treatment of HCC [118]. 27 is currently available in Israel to treat liver cancer patients through compassionate use when all available treatment options have been exhausted. Can-Fite has recently reached an agreement with the FDA and EMA to begin a more extensive phase 3 clinical trial to treat liver cancer.

Elevation of IOP induces impairment and apoptotic death of RGCs, and A3AR agonists such as 27 and MRS-3558 (28, Fig. 10) preserve RGCs from apoptosis induced by P2X7R activation (e.g., ATP or other nucleotides). The P2X7R overexpression in RGCs is tied with other factors (e.g., increased MAPK and caspase-3 proteins in the retina), implying a pro-apoptotic mechanism in RGC death induced by elevated IOP. Recently, Sakamoto et al. reported that P2X7R activation is involved in the mechanism of NMDA-induced retinal injury, leading to glaucomatous RGC loss [119]. The treatment with 27 decreased the number of cells encountering apoptosis and, at the same time, enhancing the RGCs survival [111]. This work has proven for the first time that 27 is neuroprotective to the retina. A dual A1/A3 agonist, MRS-3630 (29, Fig. 10), was also efficacious in protecting RGCs from cell death [19].

On the other hand, the treatment with P2X7R antagonists, such as MRS-2540 (30, Fig. 11) and JNJ-47965567 (31), prevents neuronal apoptosis in the retina induced by hypoxia or ATP [101, 120].

A3AR antagonists

As stated before, A3AR has a pivotal role in IOP regulation, even though there are concerns about agonists and antagonists of A3AR that might be useful in treating the same pathologic conditions (e.g., glaucoma). Usually, topically applied A3AR agonists increased IOP, whereas A3AR antagonists decreased IOP in mice. The selective activation of A3AR can increase AH, and consequently increase IOP, by a mechanism that involves the activation of Cl− channels in the non-pigmented ciliary epithelial (NPE) cells [121, 122]. Studies on A3AR knockout mice have corroborated this observation. Avila et al. reported that the baseline IOP in A3AR knockout mice was significantly lower than that in wild-type ones, and A3AR agonists or antagonists did not affect at all IOP [105].
As a reasonable interconnection to clinical glaucoma, A3AR is upregulated by an order of magnitude in the non-pigmented ciliary epithelium in the pseudoexfoliation syndrome, the largest cause of secondary open-angle glaucoma. Considering the ability of the A3AR to act as a regulator of chloride transport in epithelial cells, its upregulation may have an additional influence on AH secretion and hence on increasing IOP [123]. This finding has opened the way to the development of selective A3AR antagonists for the treatment of glaucoma. To date, the A3AR antagonists tested for their effects on lowering IOP consisted of: the 6-phenyl-1,4-dihydropyridine derivatives MRS-1097 (32), MRS-1191 (33), the nonxanthine heterocyclic derivative MRS-1220 (34), the pyridine derivative MRS-1523 (35), the nucleoside-based antagonists MRS-1292 (36), MRS-3771 (37), MRS3826 (38), LJ-979 (39), and LJ-1251 (40), the triazolopurine derivative OT-7999 (41), PBF-677 (structure not disclosed), and ACN-1052 (structure not disclosed).

Civan et al. [124], have patented compounds 32-35 as part of a method aimed to decrease IOP by administrating an A3AR antagonist. As reported before, adenosine and A3AR agonists cause isotonic cell shrinkage by activating Cl\(^-\) channels in the basolateral membranes of NPE cells, accelerating the rate of AH formation and increasing IOP. A3AR antagonists such as 32-35 prevent Cl\(^-\) outflow and decrease AH production in NPE cells [125].

The IOP responses to A3AR antagonists were monitored in A3-knockout (A3AR\(^{-/-}\)) and control mice (A3AR\(^{+/+}\)) [105]. The highly selective A3AR antagonist 33 did not impact IOP in A3-knockout mice but lowered it in control mice (by 7.0 ± 0.9 mmHg). Instead, 35,
structurally different to 33, reduced baseline IOP in A3-
knockout mice by 3.6 ± 0.6 mmHg, but reduced the IOP in
the control mice to a more considerable extent (by 9.8 ± 1.1 mmHg). Such a phenomenon might be explained by
the relative selectivity of 35 for A2ARs over A2A AR with
respect to 33, which raises the possibility that 33 may
have cross-occupied A2A AR, leading to a decrease of IOP.
Investigation of A3 AR antagonists has often been limited
by their species variability, whereas A3 AR agonists usually
display high affinity across species. This problem has been
brilliantly overcome by modifying the highly specific,
cross-species agonist IB-MECA, providing a pool of A3 AR
antagonists (compounds 36-40) able to act across species.

The conformationally constrained ligand MRS-1292 (36,
Fig. 12), a selective A3 AR antagonist in both the human and
the rat, reduces mouse IOP and inhibits A3 AR-mediated
shrinkage of cultured human NPE cells [104]. When applied
topically, 36 generates a maximum reduction in IOP of
4.4 ± 0.8 mmHg, making it a drug of choice for additional
animal testing to fully understand the role of A3 AR in
increasing/decreasing IOP.

Of the four A3 AR antagonists (37-40) studied by Wang
et al., obtained after modification of CI-IB-MECA (27), all
of them reduced measured IOP after topical administration
(Wang et al., 2010). The 4 A3 AR antagonists’ effect on
mouse IOP was measured in two different manners: inva-
sively (by the Servo-Null Micropipette System, SNMS) and
non-invasively (by Pneumotonometry). The measurements
of IOP by SNMS tonometry demonstrate the functional
efficacy of 37-40 in the mouse, whereas their effect on the
adenosine-triggered shrinkage of native bovine NPE cells
showed that the antagonists are efficacious against bovine,
as well as human and mouse A3 ARs.

The 5′-N,N-dimethyluronamide derivative MRS-3771
(37) [126] reduced IOP of 3.0 ± 1.1 mmHg and sig-
nificantly inhibited adenosine-produced cell shrinkage of
native bovine NPE, monitored by measuring cell area
[127, 128].

The di-acetyl ester derivative of MRS-3771 (37), MRS-
3826 (38) [115], lowered IOP measured by invasively
SNMS tonometry of 4.0 ± 0.8 mmHg, but not reduced IOP
measured by pneumotonome.

LI-979 (39), an analog of CI-IB-MECA (27) obtained by
concomitant addition of a methyl group to the 5′-uronamide
and 4′-thio substitution, reduced invasive-measured IOP of
4.2 ± 1.2 mmHg at a concentration of 250 μM.
The only tested nucleoside-based derivative that lowered
IOP at a concentration of 250 μM by SNMS tonometry
(1.5 ± 0.6 mmHg) as well as by pneumotonometry (4.2 ± 0.7 mmHg) has been LI-1251 (40) [129]. 40 has been
synthesized starting from 39 by removing the 5′-uronamide
moiety, with the aim to eliminate H-bonding at that posi-
tion. Its moderate hydrophobicity (cLog P = 2.25) allowed
it to permeate the cornea remarkably quickly, although the
underlying mechanism is still unknown and requires
further study.

The triazolopurine derivative OT-7999 (41, Fig. 12),
developed by Otsuka Pharmaceutical (Japan), has been
studied to treat glaucoma. 41 was applied topically to one
eye in cynomolgus monkeys with normal IOP. The results
indicated that 41 lowered IOP of 2-3 mmHg after 2 and
4 hours of topical application, and no ophthalmologic side
effects had been detected [24, 130].

PBF-677 (structure not disclosed), a selective and
potent gastrointestinal (GI)-restricted A3 AR antagonist,
has been developed by Palobiofarma, a Spanish bio-
technology company, and has recently positively com-
pleted a “first in human” phase 1 study to assess safety and
tolerability in healthy volunteers (NCT02639975). The
drug is intended to treat glaucoma, ocular hypertension,
and eye diseases and has already received the Spanish
Regulatory Agency’s approval.

PBF-677 is also in development as a “first-in-class” oral
treatment for inflammatory bowel and is currently ongoing a
proof of concept (POC) phase 2 study for assessing safety
and efficacy in ulcerative colitis patients (NCT03773952).

Acorn Biomedical has suggested using ACN-1052
(structure not disclosed) for glaucoma treatment. ACN-
1052 is an orally bioavailable A3 AR antagonist with a
single-digit (nM) affinity for both the rat and human
A3 AR. Its pharmacodynamics has been extensively studied
in preclinical models. ACN-1052 reduced IOP after topical
administration, and with a chronic administration, it gen-
erated a prolonged effect in reducing IOP. It is worth
noting to mention that the IOP reduction obtained with
ACN-1052 is 2-fold lower than that obtained with first-line
drugs such as brimonidine tartrate (Alphagan®) or latano-
prost (Xalatan®).

Summing up, it should be pointed out that all tested
A3 AR antagonists are in the preclinical stage, except for
PBF-677 [113].

A1 AR agonists/A3 AR antagonists

Given the wide distribution of AR subtypes in all mammal
tissues, an innovative strategy that allows avoiding the side
effects represents a good starting point for selective AR
ligands’ therapeutic development. For this reason, the
emerging and alternative approach, called poly-
pharmacology, has been gaining increasing attention in the
last decade. Polypharmacology consists of modulating
multiple targets related to only one disease pathway with a
single drug. In this respect, a drug that hits multiple sensi-
tive targets (multitarget drug) offers the potential for higher
efficacy and curtails drawbacks that generally arise from the
use of combination therapies [131, 132]. Furthermore, a
multitarget drug has the benefit of following only one metabolic pattern and pharmacokinetic, which instead represent a significant constraint of the combination therapy.

In the AR arena, several examples of dual-acting ligands have been reported. A dual A2AR agonist and A3AR antagonist, called GW328267X (42, Fig. 13), has been designed by Glaxo as an anti-inflammatory agent [133]. Despite its full-blown anti-inflammatory efficacy in animal models, 42 failed to show efficacy in a clinical trial for allergic rhinitis and asthma (NCT01640990). Side effects directly linked to its agonist activity at A1AR (i.e., tachycardia and hypotension) have limited its clinical development. Later on, Hou et al. synthesized a new series of dual-acting hA2AR agonists and hA3AR antagonists with the aim to be developed for the treatment of asthma and inflammatory diseases [134]. Recently, Jacobson et al. have hypothesized that a dual A1AR antagonist and A2AR agonist may have a beneficial impact on the treatment of asthma [135].

By relying on the dual-acting ligand approach, in 2015, we reported the first highly potent dual-acting hA1AR agonists and hA3AR antagonists [136]. Combining a 5′-C-ethyltetrazol-2-yl moiety with the appropriate N6-substitution in adenosine derivatives, an increased affinity versus both hA1AR and hA3AR (at the subnanomolar range) was achieved while remaining agonists at hA1AR and antagonists at hA3AR. The follow-up paper aimed to extend the series of 5′-C-(ethyltetrazol-2-yl)adenosine and 2-chloroadenosine derivatives, modifying the substituent in the N6-position of the adenine ring [137]. This study demonstrated for the first time that all dual-acting N6-substituted 5′-C-ethyl-tetrazolyl adenosine derivatives act as antagonists at human A3AR but as agonists at the rat A3AR, highlighting the importance of species differences for both affinity and efficacy at A3AR. Additionally, this new series has allowed us to disclose N6-cyclopropylmethyl-5′-C-(ethyltetrazol-2-yl)-2-chloroadenosine (43), a very potent dual-acting A1/A3 agonist in rat and A1AR agonist/A3AR antagonist in human ARs.

Moreover, this new series of compounds may represent a set of pharmacological tools for in vivo studies with the aim of investigating the advantages of dual-acting A1AR agonists and A3AR antagonists in several diseases. A single molecule with one pharmacokinetic profile, activating one signaling pathway while blocking another one, could potentially be a promising candidate to reduce elevated IOP and have the capability to be used in the treatment of glaucoma.

This approach had previously been attempted by Inotek Pharmaceuticals, who have patented the use of combination therapy based on an A1AR agonist (i.e., trabodenoson) and an A3AR antagonist for the treatment of diseases and conditions caused by elevated IOP [138]. The results of the in vivo administration of the combination therapy showed a substantial decrease in IOP during the entire observation period (~6 h).

Conclusions

In the past two decades, a significant medicinal chemistry campaign around the ARs in the ocular therapeutic field has been conducted. The activation or blockage of ARs is involved in the modulation of IOP, retinal function, AH formation, neuroprotection, and blood flow. Data from preclinical and clinical trials are extremely encouraging and shed some light on the role of ARs in ocular diseases. Although it has been highlighted a puzzling and contradictory scenario of modulation of purinoma in the eye, the ARs ligands hold promise for future ocular therapeutics. However, a better understanding of their exact contribution to glaucoma or other ocular diseases is a crucial step in order to future design new therapeutics built on ARs agonists or antagonists.

Acknowledgements

The authors (LC and RP) thank the University of Camerino (Fondo di Ateneo per la Ricerca, FAR 2018) and the PRIN grant from the Italian Ministry of Health to R.P. (PRIN 2017CBNCYT_005) for the financial support.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. World Health Organization (WHO) (2020). Blindness-and-visual-impairment. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment Accessed 12 October 2020.

2. Adams CM, Papillon JPN (2020). Recent Developments for the Treatment of Glaucoma. In: Topics in medicinal chemistry. Berlin, Heidelberg: Springer. https://doi.org/10.1007/7355_2019_92.
3. Quigley HA, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7.
4. Aires ID, Ambrosio AF, Santiago AR. Modeling human glaucoma: Lessons from the in vitro models. Ophthalmic Res. 2017;57:77–86.
5. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.
6. Hood DC. Improving our understanding, and detection, of glaucomatous damage: An approach based upon optical coherence tomography (OCT). Prog Retin Eye Res. 2017;57:46–75.
7. Xin C, Wang RK, Song S, Shen T, Wen J, iuriin E, et al. Aqueous outflow regulation: Optical coherence tomography implicates pressure-dependent tissue motion. Exp Eye Res. 2017;158:171–86.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.
9. Kish T. Old and new drug classes expanding to include glaucoma treatments. Pharm Ther. 2018;43:489.
10. Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye. 2020;34:72–88.
11. Findlay Q, Reid K. Dry eye disease: when to treat and when to refer. Aust Prescr. 2018;41:160–3.
12. Madeira MH, Boia R, Santos PF, Ambrosio AF, Santiago AR. Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. Mediat Inflamm. 2015;2015:673090.
13. Aires ID, Boia R, Rodrigues-Neves AC, Madeira MH, Marques C, Ambrosio AF, et al. Blockade of microglial adenosine A2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia. 2019;67:896–914.
14. Chou R, Dana T, Bougatsos C, Grusping S, Blazina I. Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the U.S. Preventive Services Task Force. JAMA. 2016;315:915–33.
15. Bonilha VL. Age and disease-related structural changes in the retinal pigment epithelium. Clin Ophthalmol. 2008;2:413–24.
16. Royal National Institute of Blind People: London (2020). AntivEGF Treatment. Available at: https://www.rnib.org.uk/eye-health/eye-conditions/anti-vegf-treatment Accessed October 15 2020.
17. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current biological activity and therapeutic potential. Curr Med Chem. 2016;23:118–35.
18. Petrelli R, Scortichini M, Belardo C, Boccella S, Luongo L, Capone F, et al. Structure-based design, synthesis, and in vivo antinociceptive effects of selective A1 adenosine receptor agonists. J Med Chem. 2018;61:305–18.
19. Cappelliacci L, Barboni G, Palmieri M, Pasqualini M, Grifantini M, Costa B, et al. Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1′-C-methyl adenosine analogues. J Med Chem. 2002;45:1196–202.
20. Cappelliacci L, Franchetti P, Pasqualini M, Petrelli R, Vita P, Lavecchia A, et al. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem. 2005;48:1550–62.
21. Cappelliacci L, Franchetti P, Vita P, Petrelli R, Lavecchia A, Costa B, et al. 5′-Carbamoyl derivatives of 2′-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem. 2008;16:336–53.
22. Franchetti P, Cappelliacci L, Marchetti S, Trincavelli L, Martini C, Mazzoni MR, et al. 2′-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J Med Chem. 1998;41:1708–15.
23. Gao ZG, Tosh DK, Jain S, Yu J, Suresh RR, Jacobson KA. A1 Adenosine receptor agonists, antagonists, and allosteric modulators. The adenosine receptors. Cham: Humana Press; 2018. pp. 59–89 .
24. Maione S, de Novellis V, Cappelliacci L, Palazzo E, Vita D, Luongo L, et al. The antinociceptive effect of 2-chloro-2′-C-methyl-N6-cyclopentyladenosine (2′-Me-CPA), a highly selective adenosine A1 receptor agonist, in the rat. Pain. 2007;131:281–92.
25. Trivedi BK, Bridges AJ, Patt WC, Friebe SR, Bruns RF. N6-Bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor. J Med Chem. 1989;32:8–11.
42. Gao ZG, Jacobson KA. 2-Chloro-N6-cyclopentyladenosine, adenosine A1 receptor agonist, antagonizes the adenosine A3 receptor. Eur J Pharm. 2002;443:39–42.
43. Gao ZG, Blaustein J, Gross AS, Meltman N, Jacobson KA. N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. Biochem Pharm. 2003;65:1675–84.
44. Carlin JL, Shalini J, Gizewski E, Wan TC, Tosh DK, Xiao C, et al. Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms. Neuropharmacology. 2017;114:101–13.
45. Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Cristino L, et al. The A1 adenosine receptor as a new player in glaucoma. Invest Ophth Vis Sci. 2019;59:383–92.
46. Myers JS, Sall KN, DuBiner H, Slomowitz N, McVicar W, Rich CC, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily oral trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharm Ther. 2016;32:555–62.
47. Kosmowska K, Ossowska K, Głowacka U, Wardas J. Toremiflorolytic effect of 5'-Chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the histamine-induced model in rats. CNS Neurosci Ther. 2017;23:438–46.
48. Luongo L, Petrelli R, Gatta L, Giordano C, Guida F, Vita P, et al. Trabodenoson, an adenosine mimetic with A1 receptor selectivity, lowers intraocular pressure by increasing conventional outflow facility in mice. Invest Ophth Vis Sci. 2018;59:324–42.
49. Klar J, Von Degenfeld G, Lerchen HG, Albrecht-Kupper B, Knorr A, Sandner P, et al. Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension. WO2012/028585. 2012:8:2012. filled March
50. Li G, Torrejon KY, Unser AM, Ahmed F, Navarro ID, Crosson CE, et al. Structure-activity relationships of the sustained effects of locally delivered agonists of the adenosine A2A receptor. Expert Rev Clin Pharm. 2010;3:55–72.
51. Albrecht-Küpper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8:91–99.
52. Kiesman WF, Elzein E, Knorr A, Sandner P, et al. Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension. WO2012/028585. 2012:8:2012. filled March
53. Kiesman WF, Elzein E, Zablocki J. A1 Adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharm. 2009;193:25–58.
54. Dal Ben D, Lampertucci C, Buccioni M, Marti Navia A, Marucci G, Spinaci A, et al. Non-nucleoside agonists of the adenosine receptors: an overview. Pharmaceuticals. 2019;12:150.
55. Voors AA, Díngen HD, Senni M, Nodari S, Agostoni P, Ponikowski P, et al. Safety and tolerability of Neladenoson Bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharm. 2017;57:440–51.
56. Albrecht-Küpper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8:91–99.
57. Klar J, Von Degenfeld G, Lerchen HG, Albrecht-Kupper B, Knorr A, Sandner P, et al. Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension. WO2012/028585. 2012:8:2012. filled March
58. Baltos JA, Vecchio EA, Harris MA, Qin CX, Ritchie RH, Christopoulos A, et al. Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. Biochem Pharm. 2017;135:79–89.
59. Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, et al. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2019;21:1426–33.
60. Crosson CE. Adenosine receptor activation modulates intracerebral pressure in rabbits. J Exp Pharm. 1995;273:320–6.
61. Avila MY, Stone RA, Civan MM, A(1A), A(2A) and A(3) subtype adenosine receptors modulate intracerebral pressure in the mouse. Br J Pharm. 2001;134:241–5.
62. Crosson CE, Petrovich M. Contributions of adenosine receptor activation to the ocular actions of epinephrine. Invest Ophth Vis Sci. 1999;40:2054–61.
63. Li B, Rosenbaum PS, Jennings NM, Maxwell KM, Roth S. Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp Eye Res. 1999;68:9–17.
64. Dos Santos-Rodrigues A, Pereira MR, Brito R, de Oliveira NA, Pues-de-Carvalho R. Adenosine transporters and receptors: Key elements for retinal function and neuroprotection. Vitam Horm. 2015;98:487–523.
65. Wurm A, Panninicke T, Landiev I, Francke M, Holforn M, Wiedemann P, et al. Purinergic signaling involved in Muller cell function in the mammalian retina. Prog Retin Eye Res. 2011;30:324–42.
66. Ahmad S, Fattech N, El-Sherbiny NM, Naime A, Ibrahim AS, El-Sherbiny A, et al. Potential role of A2A adenosine receptor in traumatic optic neuropathy. J Immunol. 2013;264:54–64.
67. Konno T, Murakami A, Uchibori T, Nagai A, Kogi K, Nakahata N. Involvement of adenosine A2A receptor in intracerebral pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1-hexyn-1-yl)adenosine. J Pharm Sci. 2005;97:501–9.
68. Mantell S, Jones R, Trehethick M. Design and application of locally delivered agonists of the adenosine A2A receptor. Expert Rev Clin Pharm. 2010;3:55–72.
69. Hothersall JD, Guo D, Sarda S, Sheppard RJ, Chen H, Keur W, et al. Structure-activity relationships of the sustained effects of adenosine A2A receptor agonists driven by slow dissociation kinetics. Mol Pharm. 2017;91:235–48.
70. Donegan RK, Lieberman RL. Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions. J Med Chem. 2016;59:788–809.
71. Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway in glaucoma: initiating and downstream mechanisms. Prog Brain Res. 2015;220:37–57.
72. Mac Nair CE, Nickells RW. Neuroinflammation in glaucoma and optic nerve damage. Prog Mol Biol Transl Sci. 2015;134:343–63.
73. Madeira MH, Elvas F, Boia R, Gonçalves FQ, Cunha RA, Ambrósio AF, et al. Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure. J Neuroinflamm. 2015;12:115.
74. de Lera Ruiz M, Lim YH, Zheng J. Adenosine A2A receptor as a drug discovery target. J Med Chem. 2014;57:3623–50.
75. Boia R, Elvas F, Madeira MH, Aires ID, Rodrigues-Neves AC, Traihão P, et al. Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage. Cell Death Dis. 2017;8:e3065.
76. Jakkola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human
A2A adenosine receptor bound to an antagonist. Science. 2006;322:1211–7.
77. Carpenter B, Lebon G. Human Adenosine A2A receptor: molecular mechanism of ligand binding and activation. Front Pharm. 2017:8:898.
78. Liu X, Huang P, Wang J, Yang Z, Huang S, Luo X, et al. The effect of A2A receptor antagonist on microglial activation in experimental glaucoma. Invest Ophth Vis Sci. 2016:57:776–86.
79. Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Invest Drugs. 2009:18:1619–31.
80. Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, et al. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2A Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia. 2017:19:530–6.
81. Madeira MH, Boia R, Elvas F, Martins T, Ambroso AF, Santiago AR. Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury. Transl Res. 2016;169:112–28.
82. Deng Q, Lim YH, Anand R, Yu Y, Kim JH, Zhou W, et al. Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists. Bioorg Med Chem Lett. 2015:25:2958–62.
83. Flohr A, Moreau JL, Poli SM, Riemer C, Steward L. 4-Hydroxy-4-yl-benzothiazol-2-yl)-amide. US-20050261289. 2005;24:2005.
84. Basu S, Barawkar DA, Thorat S, Shejul YD, Patel M, Naykodi M, et al. Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation. J Med Chem. 2017:60:681–94.
85. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharm Rev. 2011:63:1–34.
86. Blazynski C. Characterization of adenosine A2 receptors in bovine retinal pigment epithelial membranes. Exp Eye Res. 1993;56:595–9.
87. Newman EA. Calcium increases in retinal glial cells evoked by light-induced neuronal activity. J Neurosci. 2005;25:5502–10.
88. Zhang M, Budak MT, Wang P, Wang J, Huang S, Luo X, et al. The effect of A2A receptor antagonist on microglial activation in experimental glaucoma. Invest Ophth Vis Sci. 2016:57:776–86.
89. Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Invest Drugs. 2009:18:1619–31.
90. Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, et al. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2A Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia. 2017:19:530–6.
91. Madeira MH, Boia R, Elvas F, Martins T, Ambroso AF, Santiago AR. Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury. Transl Res. 2016;169:112–28.
92. Deng Q, Lim YH, Anand R, Yu Y, Kim JH, Zhou W, et al. Use of molecular modeling aided design to dial out hERG liability in adenosine A2A receptor antagonists. Bioorg Med Chem Lett. 2015:25:2958–62.
93. Flohr A, Moreau JL, Poli SM, Riemer C, Steward L. 4-Hydroxy-4-yl-benzothiazol-2-yl)-amide. US-20050261289. 2005;24:2005.
94. Basu S, Barawkar DA, Thorat S, Shejul YD, Patel M, Naykodi M, et al. Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation. J Med Chem. 2017:60:681–94.
95. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharm Rev. 2011:63:1–34.
96. Blazynski C. Characterization of adenosine A2 receptors in bovine retinal pigment epithelial membranes. Exp Eye Res. 1993;56:595–9.
97. Newman EA. Calcium increases in retinal glial cells evoked by light-induced neuronal activity. J Neurosci. 2005;25:5502–10.
98. Zhang M, Budak MT, Lu W, Khurana TS, Huang S, Luo X, et al. The effect of A2A receptor antagonist on microglial activation in experimental glaucoma. Invest Ophth Vis Sci. 2016:57:776–86.
99. Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Invest Drugs. 2009:18:1619–31.
113. Chen J, Runyan SA, Robinson MR. Novel ocular anti-hypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667–70.
114. Wang Z, Do CW, Avila MY, Stone RA, Jacobson KA, Civan MM. Barrier qualities of the mouse eye to topically applied drugs. Exp Eye Res. 2007;85:105–12.
115. Besada P, Mamedova LK, Palaniappan KK, Gao ZG, Joshi B, Jeong LS, et al. Nucleoside prodrugs of A3 adenosine receptor agonists and antagonists. Coll Czech Chem Comm. 2006;71:912–28.
116. Bar-Yehuda S, Luger D, Ochaion A, Cohen S, Patokaa R, Zozulya G, et al. Inhibition of experimental autoimmune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med. 2011;28:727–31.
117. Fishman P, Salhab A, Cohen S, Amer J, Izhak I, Barer F, et al. The anti-inflammatory and anto-fibrogenic effects of namodeenosin in NAFLD/NASH animal models. Abstract Thu-487. J Hepatol. 2018;S349–S350.
118. Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, et al. A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. Pain. 2014;155:2560–6.
119. Sakamoto K, Endo K, Suzuki T, Fujimura K, Kurachi Y, Mori A, et al. P2X7 receptor antagonists protect against N-methyl-D-aspartic acid-induced neuronal injury in the rat retina. Eur J Pharmacol. 2015;756:52–58.
120. Mělík Parsadaniantz S, Réaux-le Goazigo A, Sapienza A, Habas C, Baudouin C. Glaucoma: a degenerative optic neuropathy related to neuroinflammation? Cells. 2020;9:535.
121. Carré DA, Mitchell CH, Peterson-Yantorno K, Coca-Prados M, Civan MM. Similarity of A3-adenosine and swelling-activated Cl− channels in nonpigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2004;287:C440–C451.
122. Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res. 2004;78:625–31.
123. Schlotzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse FE, Junemann A, et al. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophth Vis Sci. 2005;46:2023–34.
124. Civan MM, Stone RA, Mitchell CH, Jacobson KA. Methods for reducing intraocular pressure using A3 adenosine receptor antagonists (US6,528,516B1). 2003; US: University of Pennsylvania.
125. Mitchell CH, Peterson-Yantorno K, Carré DA, McGlinn AM, Coca-Prados M, Stone RA, et al. A3 adenosine receptors regulate Cl− channels of nonpigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 1999;276:C659–C666.
126. Gao ZG, Joshi BV, Klutz AM, Kim SK, Lee HW, Kim HO, et al. Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5′-ribofuran-uronomide moiety. Bioorg Med Chem Lett. 2006;16:596–601.
127. Do CW, Peterson-Yantorno K, Mitchell CH, Civan MM. cAMP-activated maxiCl− channels in native bovine pigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2004;287:C1003–1011.
128. Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, et al. Pharmacological characterization of novel A(3) adenosine receptor-selective antagonists. Neuropharmacology. 1997;36:1157–65.
129. Jeong LS, Cheo SA, Gunaga P, Kim HO, Lee HW, Lee SK, et al. Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4′-thioadenosines derivatives without 4′-hydroxymethyl group as highly potent and selective antagonists. J Med Chem. 2007;50:3159–62.
130. Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiyu K, et al. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett. 2004;14:3775–9.
131. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57:7874–87.
132. Lavecchia A, Cerchia C. In silico methods to address polypharmacology: current status, applications, and future perspectives. Drug Disc Today. 2016;21:288–98.
133. Bevan N, Butchers R, Cousins R, Coates J, Edgar V, Morrison V, et al. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-[(6-amino-2-[[1(5S)-2-hydroxy-1-phenylmethyl ethyl]amino]-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl) tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A2A receptor agonist and adenosine A3 receptor antagonist activity. Eur J Pharmacol. 2007;564:219–25.
134. Hou X, Majik MS, Kim K, Pyee Y, Lee Y, Alexander V, et al. Structure–activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands. J Med Chem. 2012;55:342–56.
135. Gao ZG, Jacobson KA. Purinergic Signaling in Mast Cell Degranulation and Asthma Frontiers in Pharmacology. 2017;8:947–60.
136. Petrelli R, Torquati I, Kachler S, Luongo L, Maione S, Franchetti P, et al. 5′-C-Ethyl-tetrazolyl-N6-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual-acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists. J Med Chem. 2015;58:2560–6.
137. Petrelli R, Scotrichini M, Kachler S, Boccella S, Cerchia C, Torquati I, et al. Exploring the role of N6-substituents in potent dual acting 5′-C-Ethyl-tetrazolyladenosine derivatives: synthesis, binding, functional assays, and antinociceptive effects in mice. J Med Chem. 2017;60:4327–41.
138. Barman S, Baumgartner R. WO2010/127210A1. Method of reducing intraocular pressure in humans. US: Inotek Pharmaceuticals Corp. Accessed 4 Nov 2010.